Identification of novel markers of inflammation. This project will benefit Australia as it will increase basic understanding of inflammatory processes, result in a new generation of diagnostics for inflammatory diseases that could lead to earlier diagnosis and to monitor treatment, resulting in large economic and health benefit. It may lead to development of novel new therapies using monoclonal antibodies to regulate processes in immune, cardiovascular and infectious diseases. The work will gene ....Identification of novel markers of inflammation. This project will benefit Australia as it will increase basic understanding of inflammatory processes, result in a new generation of diagnostics for inflammatory diseases that could lead to earlier diagnosis and to monitor treatment, resulting in large economic and health benefit. It may lead to development of novel new therapies using monoclonal antibodies to regulate processes in immune, cardiovascular and infectious diseases. The work will generate significant economic spin-offs to the Australian biotechnology industry and will further relationships and training between research and development.Read moreRead less
Development of an anti-Chlamydia vaccine for the koala. The koala is one of Australia's main icons and a major drawcard for tourists. However, it suffers from debilitating disease due to the bacterium Chlamydia, which can lead to severe conjunctivitis, eventual blindness in both sexes, and the females develop untreatable cysts and can become infertile. This project will develop a Chlamydia vaccine to be administered to healthy and diseased koalas in zoos, sanctuaries, koala care centres, relocat ....Development of an anti-Chlamydia vaccine for the koala. The koala is one of Australia's main icons and a major drawcard for tourists. However, it suffers from debilitating disease due to the bacterium Chlamydia, which can lead to severe conjunctivitis, eventual blindness in both sexes, and the females develop untreatable cysts and can become infertile. This project will develop a Chlamydia vaccine to be administered to healthy and diseased koalas in zoos, sanctuaries, koala care centres, relocation programs and eventually perhaps even wild populations. The vaccine findings may also be transferable to other animals and may also even assist the development of a human Chlamydia vaccine.Read moreRead less
Development of an effective vaccine for chlamydial infection: optimisation of a non-toxic cholera toxin-based adjuvant to generate a protective mucosal response. Chlamydial genital infections are the most common sexually transmitted infection in Australia and the world and impose a major health burden on the community. Chlamydial infections are also associated with cardiovascular disease, Australia's biggest killer and asthma, another condition that has increased significantly in prevalence in t ....Development of an effective vaccine for chlamydial infection: optimisation of a non-toxic cholera toxin-based adjuvant to generate a protective mucosal response. Chlamydial genital infections are the most common sexually transmitted infection in Australia and the world and impose a major health burden on the community. Chlamydial infections are also associated with cardiovascular disease, Australia's biggest killer and asthma, another condition that has increased significantly in prevalence in the past 10 years. This project will evaluate the effectiveness of a new adjuvant as a first step towards the development of a vaccine to target these important infections.Read moreRead less
Novel lipid-based adjuvants for induction of mucosal immunity. The project will determine if needle-free oral and transcutaneous immunisation using LipoVax, a novel lipid-based antigen delivery system developed by the industry partner, can protect mice against the mucosal pathogens Chlamydia and Helicobacter. We expect to show that this immunisation method can induce protective mucosal immunity against two of the most common infectious organisms affecting mankind. If successful this will allow u ....Novel lipid-based adjuvants for induction of mucosal immunity. The project will determine if needle-free oral and transcutaneous immunisation using LipoVax, a novel lipid-based antigen delivery system developed by the industry partner, can protect mice against the mucosal pathogens Chlamydia and Helicobacter. We expect to show that this immunisation method can induce protective mucosal immunity against two of the most common infectious organisms affecting mankind. If successful this will allow us to develop LipoVax as a new platform technology that can be applied to the development of human vaccines, veterinary vaccines, vaccines for companion animals and vaccines to target infections in feral animals and native wildlife population populations.Read moreRead less
Enhancing immunogenicity of DNA vaccines by targeted delivery to antigen presenting cells. Vaccines have proven to be one of the most effective means of preventing infection and also provide promise as a treatment for cancer. However, the range of effective technologies that make possible the delivery of vaccines that can protect against a broad range of infections is limited. DNA based vaccines are attractive because they are relatively easy to produce against a wide range of infections. Howeve ....Enhancing immunogenicity of DNA vaccines by targeted delivery to antigen presenting cells. Vaccines have proven to be one of the most effective means of preventing infection and also provide promise as a treatment for cancer. However, the range of effective technologies that make possible the delivery of vaccines that can protect against a broad range of infections is limited. DNA based vaccines are attractive because they are relatively easy to produce against a wide range of infections. However, DNA vaccines often provide poor protection against infections. This project will explore a unique technology developed in Australia and that will greatly improve the effectiveness of DNA vaccines against a broad range of diseases. Read moreRead less
Development of purified antibodies that kill virus infected cells. This proposal will develop panels of purified and monoclonal antibodies that kill virus infected cells. These antibodies may show efficacy in preventing HIV infection. This is new technology that could subsequently be harnessed to protect or limit the devastating effects of chronic viruses such as HIV.
Characterisation and development of adjuvants for new generation veterinary and human vaccines. Vaccination is the most successful and cost-effective means of combating infectious diseases in both veterinary and human medicine. This project will increase our understanding of how vaccines work and will help the development of new vaccines against infections in both animals and man. The results of these studies will also increase the competitiveness of Australian scientists in the field of vaccine ....Characterisation and development of adjuvants for new generation veterinary and human vaccines. Vaccination is the most successful and cost-effective means of combating infectious diseases in both veterinary and human medicine. This project will increase our understanding of how vaccines work and will help the development of new vaccines against infections in both animals and man. The results of these studies will also increase the competitiveness of Australian scientists in the field of vaccine research and development.Read moreRead less
Equine rhinitis A virus; molecular pathogenesis and methods for control. The horse industry in Australia is primarily based in rural locations and is a major contributor to the national economy both in terms of direct economic contribution to gross domestic product and as a major employer of people in regional Australia. The research proposed in this project will improve our understanding of the pathogenesis of a virus that causes respiratory disease in horses that is related to the virus that c ....Equine rhinitis A virus; molecular pathogenesis and methods for control. The horse industry in Australia is primarily based in rural locations and is a major contributor to the national economy both in terms of direct economic contribution to gross domestic product and as a major employer of people in regional Australia. The research proposed in this project will improve our understanding of the pathogenesis of a virus that causes respiratory disease in horses that is related to the virus that causes foot and mouth disease in ruminants and swine. The technology developed during this project would have a global market.Read moreRead less
Immunological mechanisms underlying the protective immune responses induced by botulinum oil adjuvanted vaccine. Botulism is recognised as an important bacterial pathogen in commercial beef cattle in Australia and around the world. Development of affective, well-researched vaccine against Clostridium botulinum is a high priority for the cattle industry. A novel oil adjuvanted vaccine (Singvac from Fort Dodge Pty Ltd) has advantage over conventional vaccines as it provides full protection follo ....Immunological mechanisms underlying the protective immune responses induced by botulinum oil adjuvanted vaccine. Botulism is recognised as an important bacterial pathogen in commercial beef cattle in Australia and around the world. Development of affective, well-researched vaccine against Clostridium botulinum is a high priority for the cattle industry. A novel oil adjuvanted vaccine (Singvac from Fort Dodge Pty Ltd) has advantage over conventional vaccines as it provides full protection following a single administration. The aims of this study are to investigate the immunological mechanisms underlying the protective response by this novel vaccine using bovine and murine models. This study will discover new control measures for botulism in Australia.Read moreRead less
Development of novel vaccine delivery systems for induction of mucosal immunity in a large animal model. The induction of mucosal immune responses is a highly desirable goal in vaccine research and development, as it prevents entry of the large number of mucosal pathogens. This proposal aims to develop new mucosal vaccine delivery systems by combining intra-nasal, intra-lung and transcutaneous vaccine delivery with ISCOM-based adjuvants. The nature of the immune response will be analysed in real ....Development of novel vaccine delivery systems for induction of mucosal immunity in a large animal model. The induction of mucosal immune responses is a highly desirable goal in vaccine research and development, as it prevents entry of the large number of mucosal pathogens. This proposal aims to develop new mucosal vaccine delivery systems by combining intra-nasal, intra-lung and transcutaneous vaccine delivery with ISCOM-based adjuvants. The nature of the immune response will be analysed in real time using a sheep cannulation model. Subsequently, the efficacy of mucosal vaccination strategies will be tested in a chlamydia infection model.Read moreRead less